Caribou Biosciences, Inc.
NASDAQ:CRBU
Overview | Financials
Company Name | Caribou Biosciences, Inc. |
Symbol | CRBU |
Currency | USD |
Price | 1.8 |
Market Cap | 162,994,860 |
Dividend Yield | 0% |
52-week-range | 1.5 - 8.33 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Rachel E. Haurwitz Ph.D. |
Website | https://cariboubio.com |
An error occurred while fetching data.
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD